SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Swinnen L, Mullen G, Carr TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood. 1995; 86: 33333340.
  • 2
    Boubenider S, Hiesse C, Goupy C, et al. Incidence and consequences of PTLD. J Nephrol. 1997; 10: 136145.
  • 3
    Swinnen LJ. Diagnosis and treatment of transplant related lymphoma. Ann Oncol. 2000; 11(Suppl. 1): 4548.
  • 4
    Ho M. Risk factors and the pathogenesis of post-transplant lymphoproliferative disorder. Transplant Proc. 1995; 27(5 Suppl. ): 3840.
  • 5
    Fisher A, Blanche S, Le Bidois, et al. Anti B-cell monoclonal antibody in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med. 1991; 324: 14511456.
  • 6
    Benkerrou M, Jais JP, Leblond V, et al. Anti B-cell monoclonal antibody treatment of severe post-transplant B-cell lymphoproliferative disorder: prognosis factors and long-term outcome. Blood. 1998; 92: 31373147.
  • 7
    Morrison V, Dunn D, Manivel C, et al. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med. 1994; 97: 1424.
  • 8
    Starzel TE, Porter KA, Iwatsuki S, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet. 1984; 1: 583587.
  • 9
    Stieber AO, Boillot O, Starzel TE. The surgical implications of post-transplant lymphoproliferative disorders. Transplant Proc. 1991; 23: 14771479.
  • 10
    Lien Y-H, Schroter GPJ, Weil IIIR, et al. Complete remission and possible immune tolerance after multidrug combination chemotherapy for cyclosporine-related lymphoma in a renal transplant patient with acute pancreatitis. Transplantation. 1991; 52: 739742.
  • 11
    Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus and induced post-transplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting [review]. Transplantation. 1999; 68: 15171525.
  • 12
    Senderowicz A, Vitetta E, Headlee D, et al. Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin. Ann Intern Med. 1997; 126: 882885.
  • 13
    Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med. 1999; 134: 445450.
  • 14
    Yedibela S, Reck T, Niedobitek G, et al. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus induced intrahepatic lymphoproliferative disorder following liver transplantation. Transpl Int. 2003; 16: 197201.
  • 15
    Verschuuren E, Stevens S, van Imhoff G, et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation. 2002; 73: 100104.
  • 16
    Oertel S, Anagnostopoulos I, Bechstein W, et al. Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation. Transplantation. 2000: 69: 430432.
  • 17
    Ganne V, Siddiqi N, Kamaplath B, et al. Humanized anti-CD20 monoclonal antibody (rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant. 2003; 17: 417422.
  • 18
    Pham P, Wilkinson A, Gritsch P, et al. Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease. Transplant Proc. 2002; 34: 11781181.
  • 19
    Berney T, Delis S, Kato T, et al. Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients. Transplantation. 2002; 74: 10001006.
  • 20
    Cook R, Connors J, Gascoyne R, et al. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet. 1999; 354: 16981699.
  • 21
    Zilz N, Olson L, McGregor C. Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation. J Heart Lung Transplant. 2001; 20: 770772.
  • 22
    Hanto DW, Frizzera F, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation. Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med. 1982; 306: 913918.
  • 23
    Hanto DW, Sakamoto K, Purtilo DT, et al. The Epstein-Barr virus in the pathogenesis of post-transplant lymphoproliferative disorders. Surgery. 1981; 90: 204213.
  • 24
    Bartlett NL, Petroni G, Parker B, et al. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma. Cancer. 2001; 92: 207217.
  • 25
    Dummer JS, Bound LM, Singh G, et al. Epstein-Barr virus-induced lymphoma in a cardiac transplant patient. Am J Med. 1984; 77: 179184.
  • 26
    Shapiro RS, Gross T, Haake R, et al. Epstein-Barr virus (EBV) associated B cell lymphoproliferative disorders (BLPD) following bone marrow transplantation (BMT) [abstract]. Blood. 1992; 80: 138a.
  • 27
    Starzl TE. Discussion of Murray JE, Wilson RE, Tilney NL, et al. Five years' experience in renal transplantation with immunosuppressive drugs: survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula. Ann Surg. 1968; 168: 416435.
  • 28
    Penn I, Hammond W, Brettschneider L, et al. Malignant lymphomas in transplantation patients. Transplant Proc. 1969; 1: 106112.
  • 29
    Hanto DW, Frizzera G, Purtilo DT, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res. 1981; 41: 42534261.
  • 30
    Ghobrial I, Habermann T, Maurer M, et al. Proposed prognostic model for survival in solid organ transplant recipients with post transplant lymphoproliferative disorders (PTLD) [abstract]. Blood. 2003; 102: 329a.
  • 31
    Jones SE, Grozea PN, Miller TP, et al. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group study. J Clin Oncol. 1985; 3: 13181324.
  • 32
    Choquet S, Leblond V, Jager U, et al. Efficacy of CHOP regimen as first line therapy in posttransplantation lymphoproliferative disorders (PTLD). A retrospective study on 25 cases [abstract]. Blood. 2003; 102: 496.
  • 33
    Swinnen L, LeBlanc M, Kasamon Y, et al. Phase II study of sequential reduction in immunosuppression, interferon alpha-2b, and ProMACE-CytaBOM chemotherapy for post-transplant lymphoproliferative disorder [abstract]. Blood. 2003; 102: 403a.
  • 34
    Shammo J, Parameswaran V, Adler S, et al. CHOP chemotherapy in combination with Rituxan for the management of post-transplant lymphoproliferative disorder [abstract]. Blood. 2003; 102: 2896.
  • 35
    Sampson R, Horsfield C, Mikhaeel G, et al. Posttransplant lymphoproliferative disorder: a single centre clinicopathological study of 34 cases complicating solid organ renal transplants [abstract]. Blood. 2003; 102: 310b.
  • 36
    Oertel S, Zeidler K, Papp-Vary M, et al. Monotherapy with the anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disease. Results of a multicentre phase II study [abstract]. Blood. 2003; 102: 413a.
  • 37
    Choquet S, LeBlond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post transplantation lymphoproliferative disorders: final results of a multicenter, open label, phase II trial [abstract]. Blood. 2003; 102: 277a278a.
  • 38
    Milpied N, Vasseur V, Parquet N, et al. Humanized anti-CD 20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol. 2000; 11(Suppl.1): 113116.
  • 39
    Garnier JL, Stevenson F, Blanc-Brunat N, et al. Treatment of post-transplant lymphomas with anti-B-cell monoclonal antibodies. Recent Results Cancer Res. 2002; 159: 113122.
  • 40
    Horowitz SM, Tsai D, Twist C, et al. Rituximab is effective therapy for post-transplant lymphoproliferative disorders not responding to reduction in immunosuppression: a prospective trial in adults and children [abstract]. Proc Annu Meet Am Assoc Cancer Res. 2001; 20: 284a.